0.11 (1.08%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Very Weak
Earnings
Very Weak
Earnings
Very Weak
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Telix Pharmaceuticals Limited Sponsored ADR
Telephone
61.3.9093.3855
Address
North Melbourne, Suite 401, 55 Flemington Road, Melbourne, Victoria (VIC) 3051
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 6.28 - 18.49
Trade Value (12mth)
US$384,039.00
1 week
-3.69%
1 month
-0.59%
YTD
33.46%
1 year
-38.95%
All time high
30.36
EPS 3 yr Growth
-90.90%
EBITDA Margin
4.90%
Operating Cashflow
-$17m
Free Cash Flow Return
-2.20%
ROIC
-0.90%
Interest Coverage
1.10
Quick Ratio
1.30
Shares Outstanding (Fully Diluted)
339m
HALO Sector
Healthcare
Next Company Report Date
19-Feb-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 23 April 26 | |
| 22 April 26 | |
| 21 April 26 | |
| 21 April 26 | |
| 14 April 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | 0.01 | 0.1 | -0.02 | | | | ||
EPS (Fully Diluted) | $ | | | | | 0.01 | 0.1 | -0.02 | | | | ||
Growth | % | | | | | 104.6 | 820.4 | -121.2 | | | | ||
PE | X | | | | | N/A | 154.9 | 1,309.3 | | | | ||
EV/EBITDA | X | | | | | N/A | 88 | 72.1 | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
